Addus HomeCare Corporation (ADUS)
$
114.54
+0.18 (0.16%)
Key metrics
Financial statements
Free cash flow per share
5.5249
Market cap
2.1 Billion
Price to sales ratio
1.5722
Debt to equity
0.0494
Current ratio
1.6624
Income quality
5.2833
Average inventory
0
ROE
0.0849
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Addus HomeCare Corporation, along with its subsidiaries, delivers vital personal care services to elderly individuals, those with chronic illnesses, and disabled persons, as well as individuals at risk of hospitalization or institutionalization across the United States. The company operates through three primary segments: Personal Care, Hospice, and Home Health. The Personal Care segment is dedicated to providing non-medical support with daily activities, including bathing, grooming, oral care, feeding, dressing, medication reminders, meal planning and preparation, housekeeping, and transportation services. In the Hospice segment, Addus offers palliative nursing care, social work, spiritual counseling, homemaker assistance, and bereavement counseling for terminally ill patients and their families. Meanwhile, the Home Health segment caters to individuals requiring skilled nursing and therapies such as physical, occupational, and speech therapy during illness or post-hospitalization. The company's payor clients encompass federal, state, and local government agencies, managed care organizations, commercial insurers, and private individuals. As of December 31, 2021, Addus served consumers through 206 offices across 22 states. The gross profit stands at $375,021,000.00 highlighting the company's profitability from core operations. The company incurred an income tax expense of $25,755,000.00 indicating its tax obligations. The income before tax ratio is 0.09 reflecting the pre-tax margin. The company recorded a net income of $73,598,000.00 reflecting its profitability. Additionally, the weighted average number of shares outstanding is 17,006,000.00 highlighting the company's shareholder base. The stock is reasonably priced at $111.90 appealing to a broad range of investors. Despite having a low average trading volume of 175,258.00 indicating lower market activity, Addus HomeCare maintains a mid-range market capitalization of $2,117,073,860.00 positioning it as a steady performer. The company is a key player in the Medical - Care Facilities industry, contributing significantly to the overall market landscape. It belongs to the Healthcare sector, driving innovation and growth. This blend of stable operations and strategic market positioning makes Addus HomeCare a notable presence in its field, attracting interest from investors while fulfilling a crucial role in providing care to those in need.
Is Addus HomeCare Corporation (ADUS) a good investment?
Investing in Addus HomeCare Corporation (ADUS) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as A-, with a Bearish outlook. Always conduct your own research before investing.
What is Addus HomeCare Corporation (ADUS)'s stock forecast?
Analysts predict Addus HomeCare Corporation stock to fluctuate between $88.96 (low) and $136.72 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Addus HomeCare Corporation's market capitalization?
As of 2025-12-15, Addus HomeCare Corporation's market cap is $2,117,073,860, based on 18,483,271 outstanding shares.
How does Addus HomeCare Corporation compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Addus HomeCare Corporation has a Lower Market-Cap, indicating a difference in performance.
How can I buy Addus HomeCare Corporation (ADUS) stock?
To buy Addus HomeCare Corporation (ADUS) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ADUS. Place an order (Market, Limit, etc.).
What is the best time to invest in Addus HomeCare Corporation?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Addus HomeCare Corporation perform in the last earnings report?
Revenue: $1,154,599,000 | EPS: $4.33 | Growth: 10.74%.
Where can I find Addus HomeCare Corporation's investor relations reports?
Visit https://addus.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Addus HomeCare Corporation?
You can explore historical data from here
What is the all-time high and low for Addus HomeCare Corporation stock?
All-time high: $136.72 (2025-01-22) | All-time low: $68.57 (2022-02-24).
What are the key trends affecting Addus HomeCare Corporation stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Addus HomeCare (ADUS) and U.S. Physical Therapy (USPH). But which of these two stocks is more attractive to value investors?
zacks.com
Addus HomeCare (ADUS) possesses solid growth attributes, which could help it handily outperform the market.
zacks.com
Investors interested in stocks from the Medical - Outpatient and Home Healthcare sector have probably already heard of Addus HomeCare (ADUS) and U.S. Physical Therapy (USPH). But which of these two stocks offers value investors a better bang for their buck right now?
seekingalpha.com
Addus HomeCare Corporation ( ADUS ) UBS Global Healthcare Conference 2025 November 12, 2025 10:15 AM EST Company Participants R. Allison - CEO & Chairman of the Board Brian Poff - CFO, Executive VP, Secretary & Treasurer Heather Dixon - President & COO Conference Call Participants Albert Rice - UBS Investment Bank, Research Division Presentation Albert Rice UBS Investment Bank, Research Division I think we'll get going with our next presenter here, Addus Healthcare -- or Home care, rather, very pleased to have them participating in our conference this year.
seekingalpha.com
Addus HomeCare Corporation ( ADUS ) Q3 2025 Earnings Call November 4, 2025 9:00 AM EST Company Participants R. Allison - CEO & Chairman of the Board Brian Poff - CFO, Executive VP, Secretary & Treasurer Heather Dixon - President & COO Conference Call Participants Dru Anderson - Corporate Communications, Inc. Matthew Gillmor - KeyBanc Capital Markets Inc., Research Division Benjamin Hendrix - RBC Capital Markets, Research Division Brian Tanquilut - Jefferies LLC, Research Division Joanna Gajuk - BofA Securities, Research Division Albert Rice - UBS Investment Bank, Research Division Jared Haase - William Blair & Company L.L.C.
zacks.com
An aging global population and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry despite the macroeconomic challenges. DGX, DVA, ADUS and PNTG are well-poised to gain.
businesswire.com
FRISCO, Texas--(BUSINESS WIRE)--Addus HomeCare Corporation (Nasdaq: ADUS), a provider of home care services, today announced that Dirk Allison, Chairman and Chief Executive Officer, and Brian Poff, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Jefferies 2025 Healthcare Services Conference, September 29 - 30, 2025, in Nashville, Tennessee. In connection with the conference, there will be a live broadcast and replay of the Company's presentation.
seekingalpha.com
Q2 revenue was $349.4m, up 21.8% YoY, with adjusted EBITDA of $43.9m and operating cash flow of $22.5m. The business continues to acquire growth and has committed $1.20 in M&A per $1 of new sales over the last 3 years. Returns on capital remain low at ~8–9%, with fair value estimated at $80–$90/share.
zacks.com
The headline numbers for Addus HomeCare (ADUS) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
See all news
